소장자료
LDR | 04487nam 2200805 4500 | ||
001 | 0100803606▲ | ||
005 | 20240329142801▲ | ||
006 | m o d ▲ | ||
007 | cr#unu||||||||▲ | ||
008 | 240116s2022 us |||||||||||||||c||eng d▲ | ||
020 | ▼a9798379850128▲ | ||
035 | ▼a(MiAaPQ)AAI30505908▲ | ||
035 | ▼a(MiAaPQ)Purdue19604461▲ | ||
040 | ▼aMiAaPQ▼cMiAaPQ▲ | ||
082 | 0 | ▼a616▲ | |
100 | 1 | ▼aDamrath, John George, IV.▲ | |
245 | 1 | 0 | ▼aMultiscale Characterization of Skeletal Properties in Diabetes and Chronic Kidney Disease▼h[electronic resource]▲ |
260 | ▼a[S.l.]: ▼bPurdue University. ▼c2022▲ | ||
260 | 1 | ▼aAnn Arbor : ▼bProQuest Dissertations & Theses, ▼c2022▲ | |
300 | ▼a1 online resource(99 p.)▲ | ||
500 | ▼aSource: Dissertations Abstracts International, Volume: 85-01, Section: B.▲ | ||
500 | ▼aAdvisor: Wallace, Joseph M.▲ | ||
502 | 1 | ▼aThesis (Ph.D.)--Purdue University, 2022.▲ | |
506 | ▼aThis item must not be sold to any third party vendors.▲ | ||
520 | ▼aChronic kidney disease (CKD) affects 15% of Americans and dramatically increases their risk of skeletal fractures and fracture-related mortality. The progression of CKD is marked by abnormal biochemistries including disrupted mineral homeostasis and elevated parathyroid hormone (PTH). High PTH is linked to the bone alterations seen in CKD including cortical porosity and altered turnover. To mitigate the effects of sustained elevations in PTH, dialysis patients are commonly given calcimimetics which act by sensitizing the calcium-sensing receptor on parathyroid chief cells, lowering PTH synthesis and secretion. While calcimimetics are suggested to reduce fracture risk in dialysis patients, little is known about how these drugs impact bone tissue properties or whether they can be implemented in early CKD to prevent CKD-induced bone deterioration. Therefore, understanding how calcimimetics alter bone quality may reveal new strategies to prevent fractures in patients with CKD. While CKD represents a major global health crisis, nearly half of all CKD patients also have diabetes. Diabetes disrupts numerous physiologic systems and independently increases fracture risk by lowering bone mass and quality. Therefore, we have two major objectives in this work. Firstly, we developed a method for analyzing bone composition and material properties in a spatially resolved manner and found that calcimimetics increase mineral crystallinity and stiffness in newly formed periosteal bone while increasing relative mineralization, stiffness, and hardness in perilacunar bone. Further, we found that these properties depended on distance from the osteocyte lacunar wall. Secondly, we developed a novel combined murine model of type 1 diabetes and CKD which revealed a unique combination of detriments in structural and tissue-level bone microarchitecture, mechanical properties, and fracture toughness. Taken together, this work represents a thorough investigation of how diabetes and CKD alter bone quality on multiple scales and how calcimimetics improve bone quality in localized regions in early CKD.▲ | ||
590 | ▼aSchool code: 0183.▲ | ||
650 | 4 | ▼aHemodialysis.▲ | |
650 | 4 | ▼aDiabetes.▲ | |
650 | 4 | ▼aVitamin D.▲ | |
650 | 4 | ▼aMortality.▲ | |
650 | 4 | ▼aCrack initiation.▲ | |
650 | 4 | ▼aUrine.▲ | |
650 | 4 | ▼aInsulin.▲ | |
650 | 4 | ▼aMechanics.▲ | |
650 | 4 | ▼aBone density.▲ | |
650 | 4 | ▼aNitrogen.▲ | |
650 | 4 | ▼aOxidative stress.▲ | |
650 | 4 | ▼aHemoglobin.▲ | |
650 | 4 | ▼aElectrolytes.▲ | |
650 | 4 | ▼aCollagen.▲ | |
650 | 4 | ▼aSpectrum analysis.▲ | |
650 | 4 | ▼aPancreas.▲ | |
650 | 4 | ▼aGlucose.▲ | |
650 | 4 | ▼aFractures.▲ | |
650 | 4 | ▼aDiabetic neuropathy.▲ | |
650 | 4 | ▼aHospital costs.▲ | |
650 | 4 | ▼aEndocrine system.▲ | |
650 | 4 | ▼aBone diseases.▲ | |
650 | 4 | ▼aAnalytical chemistry.▲ | |
650 | 4 | ▼aChemistry.▲ | |
650 | 4 | ▼aMedicine.▲ | |
650 | 4 | ▼aOptics.▲ | |
650 | 4 | ▼aPharmaceutical sciences.▲ | |
650 | 4 | ▼aPublic health.▲ | |
690 | ▼a0346▲ | ||
690 | ▼a0486▲ | ||
690 | ▼a0485▲ | ||
690 | ▼a0564▲ | ||
690 | ▼a0752▲ | ||
690 | ▼a0572▲ | ||
690 | ▼a0573▲ | ||
710 | 2 | 0 | ▼aPurdue University.▲ |
773 | 0 | ▼tDissertations Abstracts International▼g85-01B.▲ | |
773 | ▼tDissertation Abstract International▲ | ||
790 | ▼a0183▲ | ||
791 | ▼aPh.D.▲ | ||
792 | ▼a2022▲ | ||
793 | ▼aEnglish▲ | ||
856 | 4 | 0 | ▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T16932761▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.▲ |

Multiscale Characterization of Skeletal Properties in Diabetes and Chronic Kidney Disease[electronic resource]
자료유형
국외eBook
서명/책임사항
Multiscale Characterization of Skeletal Properties in Diabetes and Chronic Kidney Disease [electronic resource]
발행사항
[S.l.] : Purdue University. 2022 Ann Arbor : ProQuest Dissertations & Theses , 2022
형태사항
1 online resource(99 p.)
일반주기
Source: Dissertations Abstracts International, Volume: 85-01, Section: B.
Advisor: Wallace, Joseph M.
Advisor: Wallace, Joseph M.
학위논문주기
Thesis (Ph.D.)--Purdue University, 2022.
요약주기
Chronic kidney disease (CKD) affects 15% of Americans and dramatically increases their risk of skeletal fractures and fracture-related mortality. The progression of CKD is marked by abnormal biochemistries including disrupted mineral homeostasis and elevated parathyroid hormone (PTH). High PTH is linked to the bone alterations seen in CKD including cortical porosity and altered turnover. To mitigate the effects of sustained elevations in PTH, dialysis patients are commonly given calcimimetics which act by sensitizing the calcium-sensing receptor on parathyroid chief cells, lowering PTH synthesis and secretion. While calcimimetics are suggested to reduce fracture risk in dialysis patients, little is known about how these drugs impact bone tissue properties or whether they can be implemented in early CKD to prevent CKD-induced bone deterioration. Therefore, understanding how calcimimetics alter bone quality may reveal new strategies to prevent fractures in patients with CKD. While CKD represents a major global health crisis, nearly half of all CKD patients also have diabetes. Diabetes disrupts numerous physiologic systems and independently increases fracture risk by lowering bone mass and quality. Therefore, we have two major objectives in this work. Firstly, we developed a method for analyzing bone composition and material properties in a spatially resolved manner and found that calcimimetics increase mineral crystallinity and stiffness in newly formed periosteal bone while increasing relative mineralization, stiffness, and hardness in perilacunar bone. Further, we found that these properties depended on distance from the osteocyte lacunar wall. Secondly, we developed a novel combined murine model of type 1 diabetes and CKD which revealed a unique combination of detriments in structural and tissue-level bone microarchitecture, mechanical properties, and fracture toughness. Taken together, this work represents a thorough investigation of how diabetes and CKD alter bone quality on multiple scales and how calcimimetics improve bone quality in localized regions in early CKD.
주제
Hemodialysis.
Diabetes.
Vitamin D.
Mortality.
Crack initiation.
Urine.
Insulin.
Mechanics.
Bone density.
Nitrogen.
Oxidative stress.
Hemoglobin.
Electrolytes.
Collagen.
Spectrum analysis.
Pancreas.
Glucose.
Fractures.
Diabetic neuropathy.
Hospital costs.
Endocrine system.
Bone diseases.
Analytical chemistry.
Chemistry.
Medicine.
Optics.
Pharmaceutical sciences.
Public health.
Diabetes.
Vitamin D.
Mortality.
Crack initiation.
Urine.
Insulin.
Mechanics.
Bone density.
Nitrogen.
Oxidative stress.
Hemoglobin.
Electrolytes.
Collagen.
Spectrum analysis.
Pancreas.
Glucose.
Fractures.
Diabetic neuropathy.
Hospital costs.
Endocrine system.
Bone diseases.
Analytical chemistry.
Chemistry.
Medicine.
Optics.
Pharmaceutical sciences.
Public health.
ISBN
9798379850128
관련 인기대출 도서